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Pifferent Effects of a High-Cholesterol Diet
n Ischemic Cardiac Dysfunction and Remodeling
nduced by Coronary Stenosis and Coronary Occlusion
iroyuki Yaoita, MD, Kazuyuki Yoshinari, MD, Kazuhira Maehara, MD, Masahito Sando, MD,
enichi Watanabe, MD, Yukio Maruyama, MD
ukushima, Japan
OBJECTIVES The aim of the study was to assess whether and how the high-cholesterol diet (HCD)-related
worsening of heart failure differs between coronary stenosis (CS)-induced myocardial
ischemia and coronary occlusion-induced myocardial infarction (MI).
BACKGROUND An HCD, a risk factor for coronary artery disease, also worsens ischemic heart failure.
Although accelerated coronary plaque formation may be a cause of this, other mechanism(s),
such as its effects through the coronary microcirculation, remain to be clarified.
METHODS In rats fed a normal chow diet or HCD, CS or MI was created surgically, and we assessed
left ventricular (LV) function by echocardiography and myocardial inflammation by histo-
pathology. In the CS groups, CS severity by histopathology, myocardial perfusion by
microspheres, myocardial protein kinase C (PKC) translocation by Western blotting, and
myocardial endothelial nitric oxide (NO) function were also investigated by the in vitro
myocardial oxygen consumption method.
RESULTS Coronary stenosis impaired myocardial endothelial NO function and reduced coronary flow
reserve, evoking myocardial ischemia, as shown by PKC- activation, myocardial inflamma-
tion, fibrosis, cardiac dysfunction, and remodeling. By itself, HCD greatly augmented such
CS-induced myocardial abnormalities without modulating the CS severity. Such detrimental
effects of HCD were ameliorated by supplying a cofactor of endothelial NO synthase—
tetrahydrobiopterin. In contrast, MI-induced heart failure was not aggravated by HCD.
CONCLUSIONS The CS-induced ischemic myocardium seems to be more susceptible to the pro-inflammatory
effect of HCD than infarcted myocardium, leading to aggravation of LV dysfunction and
remodeling via modification of the coronary circulation downstream of the epicardial CS site,
partly through impairment of endothelial NO. (J Am Coll Cardiol 2005;45:2078–87)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.03.037© 2005 by the American College of Cardiology Foundation
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bietary cholesterol in excess promotes coronary plaque
ormation, which increases the susceptibility to myocardial
schemia and aggravates ischemic heart disease (1–3).
oreover, a cholesterol burden closely related to a contin-
ous high-cholesterol diet (HCD) impairs coronary endo-
helial nitric oxide synthase (eNOS) activity in small vessels,
s well as in conduit vessels through formation of complexes
f eNOS protein and inhibitory caveolin (4). Coronary
icrovascular eNOS dysfunction impairs the regulation of
oronary flow and mitochondrial respiration (5) and pro-
otes inflammatory cell infiltration (6,7). Although acute
yocardial ischemia-reperfusion injury is aggravated by
holesterol burden (6), it remains to be clarified whether and
ow cholesterol burden aggravates cardiac function in the
nfarcted heart and in the ischemic heart with chronic
oronary stenosis (CS) without modulating the severity of
S. Myocardial damage induced by HCD, if any, may not
e the same in the two ischemic conditions—that is,
nfarcted or ischemic but viable myocardium. Therefore, in
he animal models of these conditions, we assessed how
ifferent kinds of myocardial ischemia due to CS or myo-
From the First Department of Internal Medicine, Fukushima Medical University,
ukushima, Japan.o
Manuscript received June 3, 2004; revised manuscript received February 28, 2005,
ccepted March 10, 2005.ardial infarction (MI) are involved in the worsening of
eart failure by HCD and also how HCD affects endothelial
O dysfunction.
ETHODS
his investigation conformed to the Guideline on Animal
xperiments of Fukushima Medical University, the Japa-
ese Government Animal Protection and Management
aw (no. 115), and the Guide for the Care and Use of
aboratory Animals published by the U.S. National Insti-
utes of Health (NIH publication no. 85-23, revised 1996).
iets. Male Sprague-Dawley rats were divided into two
roups: the normal chow diet (NCD) group (n  252) and
he 2% HCD (8) group (n  268), which was started at
even weeks of age. Either CS or MI was created at 10
eeks of age in rats on NCD and at nine weeks of age in rats
n HCD to minimize differences in body and heart weights
etween the two groups.
oronary stenosis and MI. Coronary stenosis was created
n rats (Fig. 1), according to our previous reports (9,10),
ith the modification using 325 m diameter thread
nstead of 275 m (9,10). Briefly, rats were anesthetized by
ntraperitoneal administration of 45 mg/kg sodium pento-
arbital and, under artificial ventilation, the left chest was
pened. Then, the proximal portion of the left coronary
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June 21, 2005:2078–87 Cholesterol Burden in Heart Failurertery, 1 to 2 mm below its origin from the aorta, was
ccluded together with the thread using the surgical strings
ollowed by thread removal. Transient coronary occlusion
nd recanalization were confirmed by the elevation of the
T-segment exceeding an R-wave amplitude on an electro-
ardiographic limb lead II and its reversal, respectively.
hen, the left chest was closed, and the rats were allowed to
ecover.
Myocardial infarction (Fig. 1) was made by ligation at the
quivalent site of the left coronary artery, which was
onfirmed by persistent ST-segment elevation.
Thirty-five cases with either persistent ST-segment ele-
Abbreviations and Acronyms
CS  coronary stenosis
eNOS  endothelial nitric oxide synthase
HCD  high-cholesterol diet
IPC  ischemic preconditioning
L-NAME  N--nitro-L-arginine methyl ester
LV  left ventricular
MCP-1  monocyte chemoattractant protein-1
MI  myocardial infarction
MVO2  myocardial oxygen consumption
NCD  normal chow diet
NO  nitric oxide
PKC  protein kinase C
igure 1. A diagram of experimental groups. Echocardiography (not show
ormal chow diet (NCD)- and high-cholesterol diet (HCD)-coronary ste
as performed before and four weeks after CS. *Myocardial oxygen cons
CD-sham without ischemic preconditioning (IPC) (Fig. 6) and n  7
lectrocardiogram; ED1  the antibodies against monocytes; MCP1  monocyt
inase C.ation after thread removal or fatal arrhythmia just after
reating CS or MI were excluded from the study.
Rats that recovered from the surgery (n  236 in the
CD group, n  249 in the HCD group) were returned to
heir cages and allowed free access to food and water until
hey were sacrificed at 1 day or 1, 4, or 12 weeks later.
lood pressure and heart rate in the awake state. Systolic
lood pressure and heart rate in the awake state were
easured by the tail-cuff method before and 4, 8, and 12
eeks after surgery.
chocardiography. Using the echocardiographic equip-
ent (a 10-MHz probe and a Hewlett Packard Sonos 100),
V end-diastolic and end-systolic diameters and LV ejec-
ion fraction were obtained by the Pombo method (9,10)
efore and 4, 8, and 12 weeks after surgery (not shown in
ig. 1).
n vitro myocardial oxygen consumption (MVO2) mea-
urement. We measured the functional activity of myocar-
ial at NO 24 h after surgery in the sham and CS groups
n  7 each; Fig. 1). Under anesthesia, the risk area was
etermined by infusing Evans blue into the ascending aorta
t a perfusion pressure of 100 mm Hg after reoccluding the
revious CS site. As described previously (5,9), myocardial
issue of the risk area, weighing about 30 mg, was bathed in
rebs’ solution; then, oxygen uptake by myocardial speci-
ens (MVO2) was measured in the chamber polarographi-
the figure) was performed before, 4, 8, and 12 weeks after surgery. In the
(CS) groups with tetrahydrobiopterin supplementation, echocardiography
on (MVO2) study not done; **among total n  13, n  6 for NCD- or
CD- and HCD-sham with IPC. CFR  coronary flow reserve; ECG n in
nosis
umpti
for Ne chemoattractant protein-1; MI  myocardial infarction; PKC  protein
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Cholesterol Burden in Heart Failure June 21, 2005:2078–87ally (5,9). The principle of this method is that the mito-
hondrial respiratory chain and cytochrome c oxidase
ctivity are suppressed by NO in a concentration-dependent
anner (5). Myocardial oxygen demand was measured for 5
in (i.e., decrease of oxygen content in the buffer/min/wet
) and calculated as a rate (%) of decrease in MVO2 of the
uffer. Then, after 104 mol/l bradykinin (to assess brady-
inin receptor-mediated endothelial NO effect) or 104
ol/l sodium nitroprusside was added to the bath. We also
ssessed the effect of pretreating the specimens with 104
ol/l N--nitro-L-arginine methyl ester (L-NAME) on
VO2 changes to confirm involvement of NO in the effect
f bradykinin.
ardiac catheterization. Four weeks (n  10 each in the
our NCD and HCD CS groups with and without tetra-
ydrobiopterin supplementation, as described later) or 12
eeks (total n 24 to 34 in the six NCD and HCD groups
ith sham, CS, or MI) after surgery, LV hemodynamics
ere measured in the anesthetized state by cardiac cathe-
erization (Fig. 1).
yocardial perfusion. One or 12 weeks after surgery,
yocardial blood flow (ml/min/wet g) and coronary flow
eserve (ml/min/wet g; maximal myocardial blood flow by
0 mg/kg/min dipyridamole infusion  basal myocardial
lood flow) in the risk area were measured by the colored
icrosphere method in six (one week, n  7 each) and four
12 weeks, n  10 to 14) subgroups, except for the MI
roups (Fig. 1), as reported previously (9,10). The risk areas
ere determined as described in the section dealing with in
itro MVO2.
emiquantitative histopathology. One (n  7 each), four
n  10 each), and 12 weeks (n  10 to 13) after surgery,
ollowing perfusion fixation with 4% paraformaldehyde at a
ressure of 100 mm Hg, we assessed CS severity (%) by the
ross-sectional areas of the coronary inner lumen (areas at
he CS site/areas at the reference site) (9,10), using light
icroscopy and the following procedure. In 5-m-thick
araffin-embedded sections stained with elastica Van
ieson, cross-sectional areas of left coronary arterial inner
umen were measured by the point counting method ofWeibel
11) by light microscopy at 200 magnification. The areas at
he stenotic site (identified by the minimal areas) divided by
he reference cross-sectional areas located 50 sections prox-
mal to the sections of the stenotic area multiplied by 100
as considered to be the degree (%) of CS (9,10).
One day (n  7 each, following the in vitro MVO2 study)
nd one week (n  7 each) or 12 weeks (n  10 to 13) after
S and one day (n  7 each) or 12 weeks (n  12 or 13)
fter MI, myocardial specimens were divided into three
hort-axial myocardial slices. From the middle slice, 5-m-
hick paraffin-embedded sections were stained with anti-
onocyte monoclonal antibodies (ED-1, Chemicon Inter-
ational, Temecula, California) or anti-monocyte
hemoattractant protein (MCP)-1 antibodies (Santa Cruz
iotechnology Inc., Santa Cruz, California) (7). The LV
ree wall was divided into five radial segments (12). The Hollowing examinations were done in the central three
egments (within the risk area). Because tissue MCP-1
ositivity was observed, especially in coronary small vessels
300 m in diameter) of the risk area, we counted
CP-1-positivity (number of MCP-1-positive vessels
300 m in diameter] per 1,000-point count area of the
hree segments) in the endocardial layers (where coronary
essels appear in their short axes) of the risk areas using the
oint counting method (11). We also assessed the grade of
yocardial fibrosis (point counts for fibrotic area/point
ounts for the three segment areas [%]), ED-1 positivity
ED-1–positive cell number per 1,000-point count area of
he three segment areas), and TUNEL positivity of cardio-
yocytes (point counts for TUNEL-positive cardiomyo-
ytes/point counts for the three segment areas [%]) (12).
yocardial fibrosis was assessed with elastica Masson stain-
ng at four (n  10 each) and/or 12 weeks (n  10 to 13)
fter surgery.
To assess the possible effect of HCD on the extent of the
isk area, in the paraffin sections of the middle short-axial
ortion of the LV stained with Evans blue (for the CS
roups) or elastica Masson (for the MI groups), a radial
ength of the trace of CS or MI divided by that of the trace
f the LV (%) was obtained 12 weeks after surgery (n  10
o 13).
estern blotting for myocardial protein kinase C (PKC). In
ix subgroups of CS and shams (n  6 each; Fig. 1), we
ssessed whether CS transmitted intracellular signals, which
re provoked by ischemia in this species (13). The ischemic
reconditioning (IPC: two episodes of 5-min coronary
cclusion followed by 5-min coronary reperfusion) was used
s a positive control (n  7 each in the NCD and HCD
ham plus IPC groups). One week after surgery, using the
omogenates of the anterior wall (the risk area) and the
osterior one-third portion of the interventricular septum
the non-risk area) in the middle LV, Western blotting for
yocardial PKC- isoform was performed and then quan-
ified by densitometry. The PKC- translocation ratio was
xpressed as PKC- density in the membrane fraction
ivided by its density in the cytosolic fraction, and we
onsidered it an approximate index of its activation. The
ata in each group are presented as the ratio (%) to that of
he NCD sham one week after surgery.
ntervention with tetrahydrobiopterin. To assess the ef-
ects of ameliorating eNOS on CS-induced heart failure, we
reated CS under general anesthesia in the NCD (n  40)
nd HCD (n  41) groups. Six hours after creating CS
hen surviving animals (n  37 each) were awake, we
tarted to administer 10 mg/kg/day tetrahydrobiopterin, a
o-factor of eNOS (NCD or HCD CS plus tetrahydro-
iopterin, dissolved in water; Fig. 1) through a cannula
ently inserted into the mouth every morning for one day,
ne week, or four weeks after CS. The doses administered
ere determined according to the previous report (14).
andomly selected groups of 27 rats each in the NCD and
CD groups were used one day (n  7 each) for in vitro
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ach) for the PKC, microsphere, and histopathologic stud-
es after CS, and the other 10 rats in each group were used
or echocardiography (the data were compared with 10 rats
ach of the NCD and HCD groups sacrificed four weeks
fter CS), catheterization, and histopathologic studies four
eeks after CS.
lood samples and liver weight. In 12-week survivors, we
easured serum lipid levels without starvation by spectro-
hotometry, norepinephrine, and vitamin C by high-
erformance liquid chromatography, as well as ascorbyl free
adicals, a marker of endogenous free radicals, by the
lectron spin trap resonance method (10).
tatistics. Data are expressed as the mean value  SE.
ultiple comparisons were performed by one-way analysis
f variance in Figures 2 through 7. If the F test results were
igure 2. Effects of NCD and HCD on left ventricular echocardiographic
ndings in rats with coronary stenosis (left) and MI (right). n  24 to 34;
or statistical analysis, n  33 each (CS groups vs. sham, NCD vs. HCD)
nd 24 each (MI groups) for Bonferroni’s post-hoc comparisons. *p 0.01
s. corresponding sham; †p 0.01 NCD-CS. (n) indicates survivors for 12
eeks. Open circles  NCD-sham (n  33); open squares  NCD-CS
n  34) or -MI (n  26); closed circles  HCD-sham (n  33); closed
quares  HCD-CS (n  34) or –MI (n  24). LVEDD  left
entricular end-diastolic diameter; LVESD  left ventricular end-systolic
iameter; LVEF left ventricular ejection fraction.; other abbreviations as
n Figure 1.
C
oigure 3. Effects of tetrahydrobiopterin (n  10 each) on left ventricular
chocardiographic findings four weeks after CS. The data on NCD- and
CD-sham (n  33 each) are the same as those in Figure 2 (for statistical
nalysis, n  10 each in other four groups for Bonferroni’s post-hoc
omparisons).Open circlesNCD; closed circlesHCD. N 33 each
n NCD- and HCD-sham. N  10 each in NCD- and HCD-CS. N 
0 each in NCD- and HCD-CS with tetrahydrobiopterin. *p  0.01, †p
0.05 vs. corresponding sham; ‡p  0.01, §p  0.05 vs. corresponding
S; p  0.01, ¶p  0.05 vs. corresponding NCD. LV  left ventricular;
ther abbreviations as in Figure 1.
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f p  0.05 was considered significant.
ESULTS
urvival rates at 12 weeks. Survival rates at 12 weeks
Table 1, Fig. 1) tended to be lower (p  NS) in the HCD
roups than in the NCD groups, as well as in the MI groups
han in the CS groups (74%, 64%, 67%, and 55% in the
CD-CS, HCD-CS, NCD-MI, and HCD-MI groups,
espectively, excluding rats sacrificed).
ody weights. Body weights (g) 12 weeks after surgery
ere higher (*p  0.05) or tended to be higher in the HCD
roups than in each corresponding NCD group (375  8,
65  12, and 359  28 in the NCD-sham, -CS, and -MI
roups, respectively, and 395 7,* 381 11, and 366 31
n the HCD-sham, -CS and -MI groups, respectively).
welve weeks after surgery, liver weight (Table 1) was larger
n the HCD group and related to obesity.
chocardiography. The LV end-diastolic and end-systolic
iameters increased, and LV ejection fraction decreased in
he NCD-CS and -MI groups compared with the NCD-
ham group, although LV end-diastolic and end-systolic
iameters were less in the NCD-CS group than the
igure 4. Myocardial blood flow and coronary flow reserve one and 12 we
o 14 at 12 weeks after surgery; for statistical analysis at 12 weeks, n  10
ham; †p  0.01, ‡p  0.05 HCD vs. corresponding NCD; §p  0.0
bbreviations as in Figure 1.CD-MI group (p  0.05 at four weeks, p  0.01 at eight gnd 12 weeks, respectively; asterisks not shown in Fig. 2).
ompared with the NCD-CS group, the HCD-CS group
ad increased LV diameters and decreased LV ejection
raction (p  0.01 each). In contrast, HCD did not affect
V diameters and LV ejection fraction in the MI groups
Fig. 2).
Four weeks after CS with tetrahydrobiopterin supple-
entation, LV end-diastolic and end-systolic diameters
ere smaller and LV ejection fraction larger than in the
orresponding NCD-CS (p  0.05 each) and HCD-CS
roups (p  0.01 each) (Fig. 3).
emodynamics in the anesthetized state. Twelve weeks
fter CS or MI, compared with the NCD- or HCD-sham
roups, LV end-diastolic pressure was greater, /dP/dt
as lower, and plasma norepinephrine was higher in the
CD- and HCD-CS and -MI groups (Table 1).
Four weeks after CS, in the NCD and HCD groups with
etrahydrobiopterin supplementation, compared with the
orresponding groups without supplementation, LV systolic
ressure did not change (e.g., 126  5 mm Hg in the NCD
roup and 123  4 mm Hg in the HCD group with
etrahydrobiopterin supplementation), but LV end-diastolic
ressure (3  1 mm Hg* vs. 8  1 mm Hg in the NCD
fter CS or sham surgery (n  7 each one week after surgery, and n  10
for Bonferroni’s post-hoc comparisons). *p  0.01 CS vs. corresponding
corresponding group without BH4. BH4  tetrahydrobiopterin; othereks a
eachroup and 4  1 mm Hg† vs. 11  2 mm Hg in the HCD
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June 21, 2005:2078–87 Cholesterol Burden in Heart Failureroup, respectively) was lower, whereas /dP/dt was
arger (i.e., 6,301  458 mm Hg/s† vs. 4,432  265
m Hg/s in the NCD group and5,921 363 mmHg/s†
s. 3,858  180 mm Hg/s in the HCD group, respec-
ively; 4,311  352 mm Hg† vs. 3,331  265 mm Hg
nd 3,873  255 mm Hg† vs. 2,551  139 mm Hg,
espectively; *p  0.05, †p  0.01).
yocardial perfusion. Myocardial blood flow decreased in
he HCD-CS group compared with the NCD-CS group,
ut coronary flow reserve decreased comparably in the
CD-CS and HCD-CS groups, compared with the cor-
esponding sham group both one and 12 weeks after
urgery. Moreover, HCD itself (HCD-sham) decreased
oronary flow reserve at both 1 and 12 weeks after surgery
Fig. 4).
Coronary flow reserve of the NCD-CS group with
etrahydrobiopterin supplementation and both myocardial
lood flow and coronary flow reserve of the HCD-CS group
ith tetrahydrobiopterin supplementation were higher than
hose of the corresponding group without supplementation
Fig. 4).
n vitro MVO2. Bradykinin decreased in vitro MVO2 24 h
fter surgery in the NCD-sham group, which was reversed
y pretreatment with L-NAME, whereas bradykinin did not
igure 5. Changes in the in vitro MVO2 by bradykinin and sodium nitropr
n the in vitro MVO2 changes by bradykinin and sodium nitroprusside in
he CS groups with NCD and HCD (n  7 in each group for Bonferron
p  0.05 HCD-CS vs. NCD-CS. P  0.05 NCD-CS  BH4 vs. NCD
anel). BK  bradykinin; SNP  sodium nitroprusside; other abbreviatioffect the HCD-sham group, regardless of pretreatment
I
cith L-NAME (Fig. 5, left panel). Moreover, bradykinin
ecreased MVO2 in the NCD-CS group but not the
CD-CS group (Fig. 5, right panel). In the NCD-CS
roup, the bradykinin-induced MVO2 decrease was smaller
han that in the NCD-sham group. Sodium nitroprusside
igure 6. Protein kinase C (PKC)- translocation ratios in myocardium at
isk one week after CS or sham surgery (n  6 each for Bonferroni’s
ost-hoc comparisons). Ischemic preconditioning (IPC) (n  7 each) was
sed as a positive control for PKC- activation by ischemia. n  6 each
roup except n  7 each in the NCD-sham  IPC and HCD-sham 
24 h after sham surgery or CS. (Left) The effect of 104 mol/l L-NAME
ham group with NCD and HCD. (Right) The effect of BH4 on those in
st-hoc comparisons). *p  0.01 vs. baseline; †p  0.01 vs. NCD-sham;
p  0.01 HCD-CS  BH4 vs. HCD-CS (asterisks not shown on right
in Figures 1 and 4.usside
the s
i’s poPC groups. *p  0.01 vs. corresponding sham; †p  0.01, ‡p  0.05 vs.
orresponding CS; §p  0.05 vs. NCD-CS. Abbreviations as in Figure 1.
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nd CS groups.
In the CS groups with tetrahydrobiopterin supplementa-
ion, the responses of in vitro MVO2 to bradykinin became
reater (Fig. 5, right panel, asterisks not shown) than in the
orresponding NCD- and HCD-CS groups without sup-
lementation.
rotein kinase C. Compared with the sham group, the
ranslocation ratios of PKC- one week after CS did not
hange in the non-risk area (105  8% of the NCD-sham
roup). In contrast, they increased in the risk areas (p 
.01 each; Fig. 6) and were higher (p  0.05) in the
CD-CS group than the NCD-CS group, and those of the
CD-CS group were comparable to the IPC group. The
ncreases in PKC- levels by CS were reversed by tetrahy-
robiopterin supplementation (p  0.05 in NCD-CS, p 
.01 in HCD-CS).
istopathology. The severity (%) of CS was not different
n the NCD and HCD groups at 1 and 4 weeks (1.6 0.1%
nd 2.0  0.1% [1 week] and 2.1  0.3% and 2.0  0.2%
igure 7. (A, left upper panels) Histopathologic findings (hematoxylin-e
agnification 40) and NCD (A-2, magnification 40), as well as MCP
agnification 200). (B, right upper panel, and C, right lower panel) M
n the sham, CS, and CS plus tetrahydrobiopterin (BH4) groups at one da
10 each for Bonferroni’s post-hoc comparisons). *p  0.01, †p  0.05 v
0.01 vs. corresponding NCD group. Abbreviations as in Figures 1 and4 weeks] in NCD- and HCD-sham groups, respectively; Cnd 56.3  8.9%* and 57.1  9.2%* [1 week] and 58.3 
.6%* and 59.8  10.4%* [4 weeks] in NCD-CS and
CD-CS groups, respectively; *p  0.01 vs. corresponding
ham) and 12 weeks after CS or sham surgery (Table 1) and
n the two tetrahydrobiopterin groups four weeks after CS
59.2  9.2%* and 58.4  10.1%*, respectively; *p  0.01
s. corresponding sham). There were no indications of
ntimal and medial thickening, thrombi, or plaque forma-
ion in any group at the CS site (data not shown).
The TUNEL positivity of cardiomyocytes was 0.01%
under the detection limit) in all groups.
Twelve weeks after surgery, the myocardial fibrosis was
imilar in the MI groups, whereas it was higher (p  0.01)
n the HCD-CS group than in the NCD-CS group (Table
). Myocardial fibrosis at four weeks after CS with supple-
entation was lower (p  0.01 each), not only in the
CD-CS group (20.7  4.1% vs. 7.2  2.8%), but also in
he HCD-CS group (55.1  9.9% vs. 15.2  2.8%),
ompared with the CS groups without supplementation.
There were no MCP-1 immunoreactivities one day after
of the anterior wall of the rats with 12-week CS and with HCD (A-1,
sitive coronary microvessels and infiltrating cells in rats with HCD (A-3,
and ED-1 positivity in myocardium at risk in rats with NCD and HCD
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icrovessels within the risk areas in the NCD- and HCD-CS
roups. Some of the infiltrating ED-1–positive cells also
howed MCP-1 positivity. The MCP-1 positivity at 1 and 12
eeks after CS was higher (p  0.01) in the HCD-CS group
han in the NCD-CS group, and one week after CS, these
alues with tetrahydrobiopterin supplementation were lower (p
0.01) in both the NCD and HCD groups than in those
ithout it. In the MI groups, there were not significantly
ifferent responses of MCP-1 positivity (positive vessel
umber/1,000-point count area) between the NCD- and
CD-MI groups (28  4* [NCD] and 34  6* [HCD] one
ay after MI and 6  1†‡ [NCD] and 6  1†‡ [HCD] 12
eeks after MI, *p 0.01, †p 0.05 vs. sham, ‡p 0.01 vs.
ne day after MI).
Compared with the corresponding shams, the ED-1
ositivity was increased in the NCD- and HCD-CS groups
t one and 12 weeks after surgery, although it showed a
rominent increase in the HCD-CS group (p  0.01 vs.
CD; Fig. 7C). One week after CS, ED-1 positivity was
ower (p  0.01) in the NCD- and HCD-CS groups with
etrahydrobiopterin supplementation than in the corre-
ponding groups without it. In contrast, in the MI groups,
here was no significant difference in ED-1 positivity
etween NCD and HCD (i.e., ED-1 positivity was 101 
9%* [NCD] and 118  21%* [HCD] one day after MI,
nd 22  7%*† [NCD] and 28  4%*† [HCD] 12 weeks
fter MI; *p 0.01 vs. sham, †p 0.01 vs. 1 day after MI).
The extent of the risk area in short-axial sections did not
iffer between the NCD and HCD groups 12 weeks after
urgery (80  10% [NCD] and 84  11% [HCD] in the
S groups, 86 14% [NCD] and 87 10% [HCD] in the
I groups).
ause of death. The postmortem examination of the
pontaneously dead rats revealed pleural effusion, suggesting
he worsening of congestive heart failure. Histopathology
evealed no positive findings, suggesting acute MI by
ematoxylin-eosin (coagulation necrosis), elastica Masson
contraction band necrosis), and TUNEL (suggestive of
poptosis) stainings.
erum lipid levels and liver weight. With HCD, serum
holesterol increased only in the sham group, and liver
eight increased (fatty liver histologically) in the HCD
roups (Table 1). Ascorbyl free radical levels were higher in
he CS and MI groups compared with the sham, irrespec-
ive of NCD or HCD.
ISCUSSION
he results of this study are summarized as follows. First,
CD did not modify LV dysfunction and remodeling
aused by MI. Second, CS impaired myocardial endothelial
O function and evoked myocardial ischemia (shown by
KC- translocation) and inflammation. Although HCD
lone did not evoke myocardial inflammation in the sham
oup, HCD aggravated these processes caused by CS-grTa
b
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Cholesterol Burden in Heart Failure June 21, 2005:2078–87nduced ischemia without modifying CS severity. As far as
e know, this is the first study to show the different effects
f HCD-induced reactions on ischemic LV dysfunction and
emodeling, as well as myocardial inflammation due to CS
nd MI.
V dysfunction and remodeling caused by ischemia and
ggravated by HCD. The myocardial NO dysfunction
ccurred soon after creating CS (Fig. 5). Shear stress
ctivates eNOS in coronary microvasculatures (15,16). Cor-
nary stenosis promoted free radical formation (17) in
schemic myocardium, expression of MCP-1 in coronary
icrovessels at risk and in some of the infiltrating cells (Fig.
), inflammatory cell infiltration, necrosis, and fibrosis. In
ddition, HCD also impaired myocardial NO function,
ven in the sham group, which is consistent with previous
eports that cholesterol burden accelerates the formation of
NOS protein and inhibitory caveolin complexes (4,18) and
isplacement of eNOS protein from caveolae, cell surface
lasma membrane invaginations (19). Impairment of myo-
ardial NO function (Fig. 5), myocardial inflammatory cell
nfiltration (Fig. 7), and LV dysfunction and remodeling
Table 1, Fig. 2), which were induced by CS, were aug-
ented by HCD and ameliorated by tetrahydrobiopterin
upplementation. Impairment of NO function induced
yocardial inflammation via coronary microvascular
CP-1 expression and ED-1–positive cell infiltration (7).
verexpression of MCP-1 alone does not cause chemotaxis
f inflammatory cells, whereas it increases the sensitivity to
ther inflammatory stimuli, functioning as an enhancer of
nflammation (20). An HCD alone does not cause vascular
nflammation. However, MCP-1, synergistically with
CD, causes monocyte infiltration (21). Taking into ac-
ount these issues, HCD may have augmented inflamma-
ion in ischemic but viable myocardium in our chronic CS
odel through the processes following eNOS dysfunction.
The contrasting effects of HCD on myocardial inflam-
ation and/or function between CS and MI would suggest
hat HCD has synergistic actions in ischemic but viable
yocardium, which is susceptible to endothelial disintegra-
ion and myocardial injury.
linical implications. Hypercholesterolemia increases the
isk of cardiac events in coronary artery disease (1–3).
tatins lower cardiac events in ischemic heart disease (1–
,22). The 4S study also revealed that the incidence of
ospitalization due to congestive heart failure was reduced
y statin therapy (1). Such increased cardiac risk from
holesterol burden may be due mainly to acceleration of
oronary plaque formation. However, it was documented
hat amelioration of nonischemic heart failure is partly due
o free radical scavenging by statins (23). Thus, impaired
oronary circulation downstream of epicardial CS and
ubsequent myocardial inflammation, especially those of the
CD-CS group, may also be therapeutic targets for future
tudies on the amelioration of heart failure.
CD in rats. Rats are resistant to increased serum lipidevels from HCD (8,24). Therefore, it is not surprising thathe increase in serum cholesterol level was slight or not
ignificant in the HCD groups. Conversely, our results
uggest that HCD is a risk factor for aggravating ischemic
eart failure, even if the serum cholesterol level is not very
igh.
tudy limitations. Our study has admitted limitations.
irst, there is inter-animal variation of the myocardial mass
endered ischemic in rats. Second, our experiment utilized a
ingle protocol for cholesterol loading, and the effects of
ifferent grades and periods of cholesterol feeding were not
ssessed. Third, data on myocardial perfusion, inflamma-
ion, and injury were not obtained at multiple time points of
V dysfunction and remodeling. Fourth, by the methods
tilized in the present study, it is difficult to totally rule out
he possibility that HCD may have triggered MI in this CS
odel. Fifth, despite comparable amelioration by tetrahy-
robiopterin of myocardial NO dysfunction (Fig. 5), myo-
ardial perfusion (Fig. 4), PKC signals (Fig. 6), and myo-
ardial inflammation (Fig. 7) in the NCD- and HCD-CS
roups, there was still some difference in LV diameters and
jection fractions between the two groups (Fig. 3). Possible
ther mechanisms, including HCD-related substances for
roducing cardiac dysfunction, need to be examined in a
uture study. Sixth, it remains to be clarified that BH4 may
ffect heart failure in our model, aside from the restoration
f eNOS, as this material has several actions, including an
nti-oxidative property.
onclusions. Although HCD did not affect epicardial CS
everity, it augmented CS-induced impairment of myocar-
ial perfusion, including eNOS function, myocardial isch-
mia, inflammation, and LV dysfunction and remodeling.
n contrast, MI-induced heart failure was not affected by
CD. These results suggest that HCD is a risk factor for
ggravating heart failure caused by CS without modifying
S severity.
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